Johnson & Johnson (JNJ) Q4 2024 Earnings Breakdown

Key Highlights:

• Overall Growth: Worldwide sales increased by 5.3% in 4Q24 and 4.3% for the full year. However, when excluding currency impacts, operational growth reached 6.7% for 4Q24 and 5.9% for the full year, showing the strength of underlying business performance.
• "Worldwide 22,520$ 21,395 5.3 % 6.7 (1.4) 88,821$ 85,159 4.3 % 5.9 (1.6)"
• U.S. Strength: The U.S. market demonstrated robust growth, with a 10.0% sales increase in both 4Q24 and the full year.
• "U.S. 13,204$ 12,009 10.0 % 10.0 - 50,302$ 46,444 8.3 % 8.3 -"
• International Headwinds: International sales were negatively impacted by currency fluctuations and saw lower operational growth. Sales declined slightly by 0.7% in 4Q24, but with currency impacts removed, operational growth was 2.5%. For the full year, international sales decreased by 0.5%, with 2.9% operational growth.
• "International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4)"
• COVID-19 Vaccine Impact: Sales from the COVID-19 vaccine are now negligible and have a limited impact on the current reporting. The analysis focuses on performance excluding these sales to reflect core business strength.
• "Worldwide excluding COVID-19 Vaccine (1) 22,520$ 21,351 5.5 % 6.9 (1.4) 88,623$ 84,042 5.5 % 7.0 (1.5)"